journal
https://read.qxmd.com/read/38124470/triplet-therapy-for-metastatic-hormone-sensitive-prostate-cancer-looking-beyond-volume-of-disease
#21
JOURNAL ARTICLE
Jenny Peng, Srikala S Sridhar, Di Maria Jiang
No abstract text is available yet for this article.
December 11, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/38073310/advances-in-understanding-and-management-of-high-grade-pancreatic-neuroendocrine-neoplasm-a-comprehensive-review
#22
JOURNAL ARTICLE
Dileep Kumar Reddy Regalla, Ojasvi Deep, Ravi Kumar Paluri
High-grade (HG) pancreatic neuroendocrine neoplasms (PAN-NENs) are aggressive and have a poor prognosis. Yet, our understanding and treatment approaches for these tumors have rapidly evolved in the past decade, despite a lack of prospective and randomized trials. It is essential to differentiate grade 3 (G3) neuroendocrine tumors (NETs) from neuroendocrine carcinomas (NECs) due to their different prognostic and treatment implications. The molecular landscape of HG PAN-NENs is complex, with mutations in key cancer-related genes, extensive genomic rearrangements, and chromosomal instability...
December 5, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/38195077/left-total-pneumonectomy-performed-after-alectinib-treatment-for-anaplastic-lymphoma-kinase-positive-lung-adenocarcinoma-a-case-report
#23
Zirong Wang, Yu Shi, Peng Zhang, Yuan Chen
BACKGROUND: Anaplastic lymphoma kinase (ALK) rearrangement generates an oncogenic ALK tyrosine kinase that activates numerous downstream signaling pathways, leading to increased cell proliferation and survival. About 5% of non-small cell lung cancer (NSCLC) patients are being diagnosed with tumor harboring ALK-positive. ALK rearrangement is an important molecular target for the treatment of NSCLC, and alectinib is a potent and highly selective second-generation ALK inhibitor. Alectinib as a neoadjuvant therapy has been reported in previous studies...
December 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/38195076/case-report-durable-response-of-gliomatosis-cerebri-with-concurrent-tumor-treating-fields-ttfields-and-chemoradiotherapy-treatment
#24
Alex M DesJarlais, Ryan Miller, Ayesha S Ali, Muneeb Z Niazi, Louis Cappelli, Jon Glass, Christopher J Farrell, Wenyin Shi
BACKGROUND: Gliomatosis cerebri (GC) is a rare and aggressive form of widely disseminated glioma infiltrating at least 3 lobes of the brain. It is a diffuse pattern of growth seen in glioma rather than a distinct pathological diagnosis based on new Word Health Organization (WHO) classification. Despite this, it is associated with worse prognosis than equally graded gliomas. Tumor treating fields (TTFields) treatment is a more recent advancement in glioma treatment delivered through low energy, intermediate frequency (200 kHz) electromagnetic fields, with multi-modal mechanisms of action...
December 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/38195075/hyperthermic-intraperitoneal-chemotherapy-for-gastric-cancer-a-narrative-review
#25
REVIEW
Courtney Chen, Monica Justo, Alexandra Gangi
BACKGROUND AND OBJECTIVE: Gastric cancer (GC) is the 5th most common malignancy globally, and although there have been modest gains in improving survival rates, it remains a leading cause of death. A component contributing to the poor survival rates includes advanced disease stage at presentation. Approximately 30-40% of GC patients present with metastases at diagnosis, with poorer outcomes when peritoneal metastases are present. However, recent studies have demonstrated potential utility of hyperthermic intraperitoneal chemotherapy (HIPEC) for GC with peritoneal carcinomatosis (GCPC) and for prevention of peritoneal carcinomatosis in high-risk patients...
December 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/38195074/establishment-and-validation-of-a-prognostic-model-for-gastric-cancer-patients-of-hebei-province-in-china
#26
JOURNAL ARTICLE
Yahui Hao, Daojuan Li, Di Liang, Yanyu Liu, Shuo Zhang, Yutong He
BACKGROUND: Hebei Province is a high-risk area for gastric cancer in China, and there is currently no survival prediction model for gastric cancer patients in Hebei Province. This study aimed to build the best survival prediction model for gastric cancer patients in Hebei Province. METHODS: The development dataset included 1,993 hospitalized gastric cancer patients from the Hebei Cancer Registration Project during 2016 and 2017. Three tree-based machine learning methods [survival trees (ST), random survival forests (RSF), and gradient boosting machines (GBM)] and Cox, were used to develop the models by ten-fold cross validation with 200 iterations...
December 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/38195073/efficacy-and-safety-of-parp-inhibitor-in-non-small-cell-lung-cancer-a-systematic-review-with-meta-analysis
#27
JOURNAL ARTICLE
Alejandro Olivares-Hernández, Jonnathan Roldán-Ruiz, José Pablo Miramontes-González, Irene Toribio-García, Juan Luis García-Hernández, Luis Posado-Domínguez, Lorena Bellido-Hernández, Juan Jesús Cruz-Hernández, Emilio Fonseca-Sánchez, Edel Del Barco-Morillo
BACKGROUND: Non-small cell lung cancer (NSCLC) has undergone a major change in the last decade in terms of survival and prognosis due to the introduction of new drugs in the last 10 years. One of the drugs with the most promising preliminary results in NSCLC are PARP inhibitors (iPARPs), whose clinical trials have very heterogeneous results. The use of iPARPs in NSCLC may lead to increased survival in several selected patients, and their use may become a standard in the coming years. However, there is currently controversy about the efficacy and safety of these drugs in NSCLC...
December 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/38073311/encouraging-prospects-with-sugemalimab-in-relapsed-or-refractory-extranodal-natural-killer-t-cell-lymphoma
#28
JOURNAL ARTICLE
Wenyu Shi, Tingxun Lu, Yidan Xu-Monette, Ken H Young
No abstract text is available yet for this article.
November 30, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/38073309/a-systematic-review-of-undifferentiated-pleomorphic-sarcoma-of-the-chest-wall
#29
JOURNAL ARTICLE
Cade Bennett, Sandeep Bharadwaj, Andrew Arndt, Akhil Chawla
BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) accounts for approximately 15% of all softtissue sarcoma (STS) cases and have a 5-year survival prognosis of around 60%. Due to its complexity, tumors are often identified by clinical and pathological exclusion. UPS is commonly found in the extremities, so finding them in the trunk and chest wall is rare. The primary objectives of this systematic review are: (I) identifying patient characteristics with lesion; (II) compiling patient outcomes following surgery; (III) identifying best therapy modalities; (IV) characterizing reported lesion histology; (V) assessing current surgical recommendations for resection; (VI) classifying lesions and their association with radiation...
November 28, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37953243/twenty-five-years-with-companion-diagnostics
#30
JOURNAL ARTICLE
Jan Trøst Jørgensen
For decades, pharmacotherapy has been hampered by significant patient variability, and the inability to predict outcomes at the individual patient level has negatively affected its value. However, progress in molecular medicine has led to an increased understanding of the pathophysiology and mechanisms of action of drugs, thereby enabling the development of predictive biomarkers. Companion diagnostics (CDx) belongs to the group of predictive biomarkers, which the Food and Drug Administration (FDA) defines as an in vitro diagnostic device that provides information that is essential for the safe and effective use of a corresponding therapeutic product...
November 6, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37953242/tumor-treating-fields-narrative-review-of-a-promising-treatment-modality-for-cancer
#31
JOURNAL ARTICLE
Tugce Kutuk, Ece Atak, Alonso La Rosa, Rupesh Kotecha, Minesh P Mehta, Michael D Chuong
BACKGROUND AND OBJECTIVE: Tumor treating fields (TTFields) therapy have emerged as a potentially effective treatment for various malignancies by delivering low-intensity, intermediate-frequency electrical fields that disrupt many processes inside cells, resulting in the interruption of cell division in cancer cells. Additionally, TTFields therapy has been found to be synergistic with existing therapeutic approaches. In this review, we provide an introduction and background to the primary mechanisms of TTFields and discuss the emerging preclinical and clinical outcomes of this novel cancer treatment technology...
November 2, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37953245/adjuvant-hepatic-arterial-infusion-chemotherapy-in-patients-with-resected-hepatocellular-carcinoma-with-microvascular-invasion
#32
JOURNAL ARTICLE
Diamantis I Tsilimigras, Timothy M Pawlik
No abstract text is available yet for this article.
October 30, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37953244/can-we-truly-define-fitness-for-car-t-therapy-in-large-b-cell-lymphoma-patients
#33
JOURNAL ARTICLE
Andy I Chen, Richard T Maziarz
No abstract text is available yet for this article.
October 24, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37872116/associations-between-marital-quality-and-the-prognosis-of-breast-cancer-in-young-chinese-women-10-3-year-median-follow-up
#34
JOURNAL ARTICLE
Lili Yuan, Huilong Cai, Weiwei An, Weiguang Yuan, Eric M Toloza, Ying Song, Jing An
BACKGROUND: Some evidence has revealed that marital status is an important predictor of breast cancer (BC) prognosis. However, what role marital quality plays in the effect of marital status on BC prognosis remains unclear. METHODS: We conducted a prospective cohort study of women aged 20-50 years with stage I-III BC treated in accordance with a standard treatment protocol. The following three categories of marital quality were assessed: marital satisfaction, sexual relationship, and couple communication...
October 20, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37817509/disease-volume-and-risk-subgroup-analyses-for-darolutamide-plus-androgen-deprivation-therapy-and-docetaxel-in-the-phase-iii-arasens-should-triplet-therapy-become-standard-of-care-in-certain-metastatic-hormone-sensitive-prostate-cancer-patients
#35
JOURNAL ARTICLE
https://read.qxmd.com/read/37817508/adjuvant-therapy-for-mucosal-melanoma-in-the-era-of-immune-checkpoint-inhibitors
#36
JOURNAL ARTICLE
Yasuhiro Nakamura, Tatsuhiko Mori
No abstract text is available yet for this article.
October 9, 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37964545/hippocampal-sparing-radiation-therapy-for-brain-metastases-treatment-techniques-and-clinical-implementation
#37
JOURNAL ARTICLE
Kaley Woods, Zhilei Liu Shen, Zhengzheng Xu, Hualin Zhang, Yutaka Natsuaki, Karen Cheng, Vivian Li, Nathan Kim, Lijun Ma, Eric Chang
High doses of radiation to the hippocampus have been correlated with increased cognitive decline following radiation therapy for brain metastases. To mitigate these effects, a variety of hippocampal sparing techniques have been implemented for both whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS). The goal of this review article is to provide a practical resource for the clinical implementation of hippocampal-sparing radiation therapy, starting with a brief background on the function and delineation of the hippocampal structure, as well as radiation effects on the hippocampus and the most widely recommended dose constraints...
October 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37964544/expression-of-yap-suppresses-cell-proliferation-and-elevates-the-sensitivity-of-chemotherapy-in-retinoblastoma-cells-through-lipid-peroxidation-induced-ferroptosis
#38
JOURNAL ARTICLE
Liting Zhong, Xuejiao Meng, Jingjing Huang, Wenwen Hao, Yajing Zuo
BACKGROUND: Retinoblastoma (RB) is a retinal cancer most commonly occurred in young children. Cisplatin and etoposide had been confirmed as chemotherapy drugs in the treatment of RB, even though the phenomenon of chemotherapeutic resistance has been occurring in clinical treatment frequently. RB has been reported to be a tumor with reduced expression of yes-associated protein (YAP). However, the role of YAP protein and its correlation with the chemotherapy effect in RB still remains unknown...
October 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37964543/targeting-erbb2-her2-genetic-alterations-an-expanding-therapeutic-opportunity-in-gastrointestinal-cancers
#39
REVIEW
Binbin Zheng-Lin, Rondell P Graham, Tanios S Bekaii-Saab
HER2 amplification and/or activating variations of its protein, human epidermal growth factor receptor 2 (HER2), are associated with distinct clinical and pathological features in gastrointestinal tumors, including a worse overall prognosis and a higher incidence of metastastic lesions in the central nervous system. Notably, the role of HER2 as a therapeutic target continues to expand beyond the scope of breast and gastroesophageal tumors, now encompassing colorectal and biliary tract cancers (BTCs), among others...
October 2023: Chinese Clinical Oncology
https://read.qxmd.com/read/37964542/boosted-abscopal-effect-from-radiotherapy-and-pembrolizumab-in-anaplastic-thyroid-cancer-a-mini-review-and-case-report
#40
Doreen Goh, Kok Hing Lim, Siti Radhziah Binte Sudirman, Mei-Kim Ang, Melvin Lee Kiang Chua, Chwee Ming Lim
BACKGROUND: The abscopal effect, in which radiation induces a systemic anti-tumour immune response, has been demonstrated with radiotherapy. Immunotherapy boosts the abscopal effect by facilitating the immune response to radiation. Radiotherapy and programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) blockade has resulted in the boosted abscopal effect in solid cancers, but its role in anaplastic thyroid cancer (ATC) is unknown. In this mini-review, we describe the abscopal effect and summarise its proposed underlying mechanisms...
October 2023: Chinese Clinical Oncology
journal
journal
47887
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.